Phase ii protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: Results of ECOG 5282

Medical Oncology

Volumn 16, Issue 4, 1999, Pages 261-266

  Novik, Y ^a   Ryan, L M ^a   Haller, D G ^a   Asbury, R ^a   Dutcher, J P ^a   Schutt, A ^a  

^a OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

Aclacinomycin A; Chemotherapy; Etoposide; Gastric cancer; Mitoxantrone; Spirrogermanium; Survival

Indexed keywords

ACLARUBICIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOXANTRONE; SPIROGERMANIUM;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STOMACH CARCINOMA; TREATMENT OUTCOME;

EID: 0033393225     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02785872     Document Type: Article

References (17)